• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Innate Pharma S.A. ADR (NQ: IPHA )

    2.080 +0.140 (+7.22%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,359
    Open 2.060
    Bid (Size) 2.000 (3)
    Ask (Size) 2.330 (3)
    Prev. Close 1.940
    Today's Range 2.060 - 2.080
    52wk Range 1.810 - 3.290
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
    From Innate Pharma SA
    Via Business Wire

    Performance

    YTD
    -23.53%
    -23.53%
    1 Month
    -24.09%
    -24.09%
    3 Month
    -22.39%
    -22.39%
    6 Month
    -23.53%
    -23.53%
    1 Year
    -30.83%
    -30.83%

    More News

    Read More
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Via InvestorPlace
    Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Announces Its Participation in Upcoming Investor Conferences
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
    From Innate Pharma SA
    Via Business Wire
    Outcome of Innate Pharma’s 2024 Annual General Meeting
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma: Clarification Regarding SAR443579 Designation
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Announces Its Participation in Upcoming Investor Conference
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
    From Innate Pharma SA
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Innate Pharma Reports Full Year 2023 Financial Results and Business Update
    From Innate Pharma SA
    Via Business Wire
    Earnings Scheduled For March 21, 2024
    Via Benzinga
    Innate Pharma Announces Its Participation to Upcoming Investor Conference
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
    From Innate Pharma SA
    Via Business Wire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
    From Innate Pharma SA
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.